Warren Brooke R, Gillette-Walch Hilary, Adler Jaime, Arias Raquel, Klausner Jeffrey D, Ashing Kimlin T, Villa Alessandro
School of Medicine, University of California, San Francisco. San Francisco, CA, United States.
Central California Alliance for Health. Scotts Valley, CA, United States.
Prev Med Rep. 2023 Feb 13;32:102144. doi: 10.1016/j.pmedr.2023.102144. eCollection 2023 Apr.
Accurate documentation of state-level human papillomavirus (HPV) vaccination is required for public health planning and to inform corrective actions. To examine the representativeness of the California Immunization Registry, we compared the National Immunization Survey (NIS)-Teen, commercial HMOs in California, Medi-Cal, and California Immunization Registry data for HPV vaccine series completion. Our objectives were to evaluate the vaccine registries, compare and report their completeness, and make recommendations on how to improve and use these studies. Vaccination values were extrapolated for all adolescents aged 13 to 17 years from 2018 to 2019 from NIS-Teen, adolescents aged 13 years from 2018 to 2019 reported in the California Immunization Registry, and adolescents aged 13 years for 2018 for commercial HMOs and Medi-Cal. HPV series completion among 13-year-olds in 2018 for commercial HMOs was 50 %, Medi-Cal was 45 %, and the California Immunization Registry was 28 %, with NIS-Teen rates for 13 to 17-year-olds at 50 % in 2018 and 54 % in 2019. Both rural and urban geographic regions were found to have low completion rates of the HPV series, with trends ranging from 13 % to 45 %. The California Immunization Registry's lower HPV vaccine series completion among 13-year-olds compared to the other reporting sources is most likely due differences in reporting and data collection. Importantly, this data will serve as a comparator for future, similar studies of various sources of HPV vaccination rates following the passing of Bill-1797, which will mandate immunization reporting starting in January 2023.
为了公共卫生规划以及为纠正措施提供信息,需要准确记录州级人乳头瘤病毒(HPV)疫苗接种情况。为了检验加利福尼亚免疫登记系统的代表性,我们比较了国家免疫调查(NIS)-青少年版、加利福尼亚的商业健康维护组织(HMO)、医疗救助计划(Medi-Cal)以及加利福尼亚免疫登记系统中HPV疫苗系列完成情况的数据。我们的目标是评估疫苗登记系统,比较并报告其完整性,并就如何改进和利用这些研究提出建议。从2018年到2019年,根据NIS-青少年版数据推断了所有13至17岁青少年的疫苗接种值,根据加利福尼亚免疫登记系统报告了2018年到2019年13岁青少年的接种值,根据商业HMO和医疗救助计划报告了2018年13岁青少年的接种值。2018年商业HMO中13岁青少年的HPV系列完成率为50%,医疗救助计划为45%,加利福尼亚免疫登记系统为28%,NIS-青少年版中13至17岁青少年2018年的完成率为50%,2019年为54%。农村和城市地理区域的HPV系列完成率均较低,范围在13%至45%之间。与其他报告来源相比,加利福尼亚免疫登记系统中13岁青少年的HPV疫苗系列完成率较低,这很可能是由于报告和数据收集方面的差异。重要的是,在第1797号法案通过后,这些数据将作为未来类似研究的比较对象,该法案将要求从2023年1月起进行免疫接种报告。